The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC).
Ana M. Aparicio(The University of Texas MD Anderson Cancer Center), Paul G. Corn(Cornell University), Bradley M. Broom(The University of Texas MD Anderson Cancer Center), Anh Hoang(The University of Texas MD Anderson Cancer Center), Patricia Troncoso(The University of Texas MD Anderson Cancer Center), Timothy C. Thompson(The University of Texas MD Anderson Cancer Center), Haidee Chancoco(The University of Texas MD Anderson Cancer Center), Naveen Ramesh(The University of Texas MD Anderson Cancer Center), Amado J. Zurita(The University of Texas MD Anderson Cancer Center), Nicholas E. Navin(The University of Texas MD Anderson Cancer Center), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Elsa Li Ning Tapia(The University of Texas MD Anderson Cancer Center), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Elisabeth I. Heath(The Barbara Ann Karmanos Cancer Institute), Wenhui Wu(The University of Texas MD Anderson Cancer Center), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center)
Cited by 20
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k